Uncommon Bio vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 35)
Uncommon Bio logo

Uncommon Bio

EmergingLife Sciences & BioTech

Cellular Agriculture & Biomanufacturing Therapeutics

Uncommon Bio (formerly Higher Steaks) pivoted from cultivated pork to therapeutic biomanufacturing in 2024–2025; its cultivated meat platform was acquired by Meatable in 2025; now focuses on scalable cell biology tools for human health applications.

AI VisibilityBeta
Overall Score
D35
Category Rank
#138 of 198
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
39
Gemini
35

About

Uncommon Bio (formerly Higher Steaks) is a UK-based biotechnology company that underwent a significant strategic pivot in 2024–2025, transitioning from cultivated meat production toward developing scalable biomanufacturing technologies for human therapeutic applications. Founded by Benjamina Bollag, the company was originally focused on developing cultivated pork products using cell culture and bioprocess engineering techniques. In 2025, Uncommon Bio's cultivated meat platform and associated intellectual property were acquired by Meatable, a Netherlands-based cultivated meat company — allowing Uncommon Bio to exit the food application space and redirect its biomanufacturing expertise toward the healthcare and therapeutics sector.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#138
Category Rank
#10
81
AI Consensus
73
stable
Trend
stable
31
ChatGPT
72
39
Perplexity
68
35
Gemini
80
34
Claude
71
32
Grok
71

Key Details

Category
Cellular Agriculture & Biomanufacturing Therapeutics
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.